NCCN Guideline Expands Locoregional Treatment Candidates in HCC


Locoregional therapies are now considered potentially curable options that should be considered alongside transplant and resection for patients with hepatocellular carcinoma.

Anne Covey, MD

Locoregional therapies are now considered potentially curable options that should be considered alongside transplant and resection for patients with hepatocellular carcinoma (HCC), according to an update of the NCCN guideline for HCC that was presented at the 2016 NCCN Annual Conference.

Locoregional treatments primarily include ablation and arterially directed therapies, alone or in combination. The updated recommendation for locoregional therapy was based on a meta-analysis of randomized controlled trials comparing radiofrequency ablation with surgical resection for patients with HCC that was <3 cm in size. In the study, the 1-, 3-, and 4-year survival rates were similar between the treatment modalities, said Anne Covey, MD, who presented the guideline at the meeting.

“The guidelines have most recently changed to include ablation as a potentially curative option,” Covey, attending radiologist at Memorial Sloan Kettering Cancer Center, said in an interview with OncLive. “It used to be that the only curative therapies were surgery or transplant, now patients can have locoregional therapy as a potential cure, and that is big.”

Ablation has the advantage of requiring fewer transfusions and a shorter hospital stay compared with resection, but it is limited by tumor location. Additionally, since the rate of local recurrence is higher with ablation, the guideline recommended that surgery and transplantation should be considered first. For ablation to be considered, hepatic tumors should be in a location accessible for percutaneous, laparoscopic, or open approaches. “Tumors near critical structures are not amenable to ablation,” Covey said.

Arterially directed therapies are generally recommended for patients who have unresectable tumors, due to inadequate hepatic reserve, tumor location, patient comorbidities, or a performance status that makes resection riskier, said Covey. Tumors may be amenable to arterially directed therapy if the arterial blood supply to the tumor may be isolated without excessive non-target treatment.

Examples of arterially directed therapies are bland embolization, transarterial chemoembolization (TACE), embolization with drug-eluting beads, and “radio” embolization with Yttrium-90. The choice of arterially directed therapy should be based on local expertise, Covey said.

“One of things we're working on, and that the guidelines will soon encompass, is imaging for locoregional therapies,” she said. “If we have principles of imaging as part of the hepatocellular guidelines that will be very helpful in guiding people into the modalities that they should use.”

For tumors 3 to 5 cm, the guideline recommends the addition of arterially directed therapy to ablation. “By doing the embolization, we may treat micrometastases or tumor around the lesion we don’t treat effectively with ablation alone,” she said. Additionally, unresectable or inoperable lesions >5 cm should be considered for treatment using arterially directed therapy or systemic therapy, according to the guideline.

Relatively new to the NCCN guideline is the inclusion of locoregional therapy for the treatment of patients with portal vein thrombus (PVT), which used to be a contraindication for locoregional therapy. The hepatic portal vein is critical to normal liver function and supplies approximately 75% of the blood supply to the liver. In general, an estimated 10% to 40% of patients with HCC will present with PVT at the time of diagnosis.

Other Locoregional Options

“The locoregional panel has also expanded to patient with minimal extrahepatic disease and patients who have portal vein thrombus, a tumor in the portal vein,” said Covey. “It's really increasing the patients who are candidates for this type of potentially life-saving treatment.”Other types of locoregional therapies were described in the guideline, including external beam radiation therapy (EBRT), stereotactic body radiotherapy (SABR), and embolization with sorafenib (Nexavar). In the case of sorafenib, this option looked promising early on, but did not seem to add benefit when added to complete ablation, according to Daniel T. Chang, MD, who also presented the new guidelines. The current recommendation is to reserve sorafenib for residual or recurrent tumors that are not amenable to additional local therapy.

EBRT (conformal or stereotactic) is a category 2B locoregional treatment recommendation for HCC inoperable hepatic tumors. Radiation can treat multiple tumors and the dose can be adjusted based on tumor size and the location of critical structures, said Chang, associate professor of radiation oncology, Stanford University.

All tumors irrespective of location may be amenable to EBRT. Tumor thrombus is not a contraindication to radiation therapy. EBRT can be combined with TACE to treat the entire tumor and to treat portal vein thrombus. TACE can also be used as a primary therapy, with EBRT for salvage. “There’s no such thing as too big [of a tumor] but of course smaller is always easier than bigger,” Chang said.

SABR or stereotactic body radiotherapy (SBRT) have the potential advantages of an improvement in local control and a compressed course of treatment, which allows for greater patient convenience and for the integration of more intensive systemic chemotherapy than could otherwise be rendered.

“Patients would rather come in for 1 week of treatment rather than 5 or 6 weeks of treatment,” said Chang, who predicted SABR/SBRT would become one of the standard treatment options for HCC for these reasons. Additionally, since the dose of radiation with SABR/SBRT is conformal to the target, “the risk of toxicity is actually quite low.”

Reactivation of hepatitis B virus is a risk with the delivery of radiation to the liver. Initiation of antiviral therapy before starting radiation likely reduces this risk, added Chang.


View more from the 2016 NCCN Annual Conference

Related Videos
Ciara Kelly, MBBCh, BAO
Mark Agulnik, MD
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Toni K. Choueiri, MD
Neil J. Shah, MBBS
Jonathan C. Trent, MD, PhD
5 KOLs are featured in this panel.
5 KOLs are featured in this panel.
Efficacy and Safety of Fruquintinib in Patients With Metastatic Colorectal Cancer According to Prior Treatment Sequence in the Refractory Setting: Results From FRESCO and FRESCO-2